Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in South Africa 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • PAIA Manuals 
      • Contacts 
      Scientist in laboratory
      About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Adverse Event Reporting 
      • Patient Support and Engagement 
      • Discovery & development 
      A couple holding hands
      Patients and Caregivers
    • Healthcare Professionals 
      • Healthcare professional country resource 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Grants & Sponsorships 
      A female doctor looking in the distance
      Healthcare Professionals
    • ESG 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      • Ethical Behavior 
      • Corporate Responsibility 
      Young patients waiting outside hospital in Rwanda
      ESG
    • News 
      • Recent News 
      • News Archive 
      • Stories 
      • Contacts 
      A photo of people in a meeting hall
      News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Personal Growth 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity and Inclusion 
      • Employee Benefits 
      • Awards & Recognition 
      Search jobs
      Careers
    • Coronavirus 
      Coronavirus
    Novartis South Africa building
    Home
Header
Patient Support and Engagement

Patient Support and Engagement

  1. Home
  2. Patients and Caregivers
  3. Patient Support and Engagement

Atherosclerotic cardiovascular disease

Atherosclerotic cardiovascular disease (ASCVD) refers to cardiovascular complications or events (such as heart attack and stroke) caused by atherosclerosis. Atherosclerosis is the build-up of fatty and fibrous deposits (plaque) within the arteries of the body. Plaque growth leads to narrowing of the blood vessels which can reduce blood flow to the brain and heart. Atherosclerosis is the main risk factor for cardiovascular disease (CVD) which is the leading cause of death worldwide

Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Chronic myeloid leukemia is caused by a genetic mutation called the Philadelphia (Ph) chromosome – a rearrangement in the genetic material between chromosomes 9 and 22. The three phases of CML include: chronic phase, accelerated-phase, and the blast phase. Most patients are diagnosed in the early, chronic phase, and if managed properly may remain in this phase without progressing to a more advance phase.

Multiple sclerosis

Multiple sclerosis (MS) is a variable disease. The symptoms you experience depend on which parts of your central nervous system (CNS) are affected by MS, and how badly they are affected.

Breast cancer

Breast cancer is a type of cancer that starts from within the cells of the breast. Although more common in women, anyone can develop breast cancer. Treatment is generally similar for women and men. Breast cancer that has spread and formed tumours in other parts of the body is referred to as metastatic breast cancer. Breast cancer screening aims to find cancer early before symptoms even present. Breast cancer that is identified earlier can be treated more successfully. Not all breast cancers are the same. The course of treatment will be determined by the treating oncologist or physician based on the results from tests including biopsies and imaging studies.

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a condition that causes small, painful lumps to form under the skin. The lumps usually develop in areas where the skin rubs together, such as the groin, buttocks, armpits, and breasts. These lumps heal slowly, are reoccurring, and can lead to tissue damage and scarring. Hidradenitis suppurativa tends to present more often in women, after puberty and before the age of 40. Although this disease is debilitating to those living with it, a combination of medical and surgical therapy can help manage the condition and prevent further complications.

Juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children under the age of 16 years, yet most cases of JIA in South Africa remain undiagnosed. This disease occurs when the body’s immune system attacks its own cells and tissues, resulting in swelling, stiffness and pain in the joints, muscles, and bones. There are several different subtypes of JIA, and a doctor (specialist) will determine the type depending on symptom presentation. Besides joint pain and swelling, other common symptoms include fatique, fever and skin rashes. Managing JIA can be challenging and overwhelming at times but if diagnosed early and treated properly, the condition can improve quickly in children.

Novartis South Africa

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Novartis South Africa
  • Global site
Footer Bottom
© 2025 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Web Accessibility
  • Cookie Settings
  • Cookie
  • Site Map
Novartis Site Directory
This site is intended to South African Republic audience